Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

PHASE4CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

April 1, 2015

Primary Completion Date

April 27, 2016

Study Completion Date

May 25, 2016

Conditions
Renal Insufficiency, ChronicAnemiaRenal DialysisErythrocyte Transfusion
Interventions
DRUG

Epoetin alfa

Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.

Trial Locations (37)

10461

Research Site, The Bronx

11102

Research Site, Astoria

11235

Research Site, Brooklyn

11422

Research Site, Rosedale

16335

Research Site, Meadville

19106

Research Site, Philadelphia

23502

Research Site, Norfolk

23666

Research Site, Hampton

27510

Research Site, Carrboro

28401

Research Site, Wilmington

30458

Research Site, Statesboro

31217

Research Site, Macon

33025

Research Site, Pembroke Pines

33150

Research Site, Miami

33169

Research Site, Miami Gardens

46360

Research Site, Michigan City

46410

Research Site, Merrillville

48066

Research Site, Roseville

48202

Research Site, Detroit

48341

Research Site, Pontiac

64111

Research Site, Kansas City

68510

Research Site, Lincoln

77004

Research Site, Houston

77070

Research Site, Houston

78229

Research Site, San Antonio

90022

Research Site, Los Angeles

90057

Research Site, Los Angeles

90606

Research Site, Whittier

90640

Research Site, Montebello

90703

Research Site, Cerritos

91204

Research Site, Glendale

92115

Research Site, San Diego

92501

Research Site, Riverside

93065

Research Site, Simi Valley

95687

Research Site, Vacaville

05401

Research Site, Burlington

00949

Research Site, Toa Baja

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY